Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Prosonix Initiates Phase 2 Clinical Study with PSX1002 in COPD Patients

Published: Thursday, May 23, 2013
Last Updated: Wednesday, May 22, 2013
Bookmark and Share
First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix’ particle engineering platform.

Prosonix has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on lung function and the safety of a range of doses in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

The first two groups of eight patients, from up to 40 patients being enrolled, have been dosed at the Medicines Evaluation Unit in Manchester, UK, where the study is being conducted under the supervision of Professor Dave Singh. Further details of the study are below.

PSX1002 is a novel formulation of glycopyrronium bromide (GB), a long-acting muscarinic antagonist (LAMA), that is being developed as a potential ‘best-in-class’ orally inhaled monotherapy for COPD.

PSX1002 was designed using Prosonix’ proprietary particle engineering technology platform, which has enabled the Company to create, and initiate clinical studies with a simple suspension formulation of GB for delivery via a pressurized metered dose inhaler (pMDI) that does not require or contain any other extraneous carriers or functional excipients.

Dr Geoff Down, Prosonix Chief Medical Officer, added: “Glycopyrronium bromide appears to be particularly useful in reversing airway constriction in COPD patients, increasing airflow, relieving symptoms and improving quality of life. We look forward to the results in 2014.”

David Hipkiss, CEO of Prosonix commented: “This trial with PSX1002 is a very exciting step for Prosonix as it marks the first ever clinical study of a drug formulation that we have wholly created and developed in-house using our unique particle engineering technology and Respiratory Medicine by Design approach. This important milestone, along with the planned EU filing of our lead product PSX1001 in the first half of 2014, highlights the rapid progress that Prosonix is making, and the significant value we are generating for all our stakeholders who have backed our respiratory focused strategy in mono and combination products.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Prosonix Reports Positive Top-line Results from its Phase 2 Clinical Study with PSX1002
First clinical data from PSX1002, a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA).
Friday, January 31, 2014
Final Patient Completes Prosonix’ Phase 2 Clinical Study with PSX1002
PSX1002 is a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA).
Monday, August 19, 2013
Prosonix Appoints Cécile Miles as Chief Business Officer
Appointment significantly strengthens corporate and commercial development experience in the generics and speciality pharmaceutical markets.
Tuesday, February 12, 2013
Prosonix Elects Dr Ken Cunningham as Non-executive Chairman
Dr Cunningham replaces Dr Jim Philips, who is retiring from the Board of Directors.
Wednesday, December 05, 2012
Prosonix Enters Collaboration with Imperial College London
Collaborative research agreement to accelerate development of engineered combination respiratory medicines.
Thursday, July 05, 2012
Prosonix Extends Series B Financing Round to £17.1M
Gimv joins syndicate of experienced life science investors - Karl Nägler joins Board as Non-executive Director.
Tuesday, May 22, 2012
Prosonix to Present at RDD 2012 and ATS 2012 International Conference
Prosonix will present a poster entitled ‘Engineered Combination Respiratory Medicines for Localized Drug Delivery’ at RDD.
Wednesday, May 09, 2012
Prosonix Demonstrates Improved Delivery and Co-localization of Respiratory Medicines
New review published in European Respiratory Disease(ERD).
Thursday, May 03, 2012
Prosonix Appoints Dr Geoff Down as Chief Medical Officer
Dr Down will oversee the clinical development of Prosonix's product pipeline.
Monday, February 06, 2012
Prosonix Appoints Rob Crocker as its First Head of Regulatory Affairs
Mr Crocker will be responsible for defining and implementing the regulatory strategy to underpin the development of Prosonix’ emerging product pipeline.
Friday, January 20, 2012
Prosonix Appoints New Scientific Advisory Board
New SAB comprises distinguished experts in respiratory disease, and in clinical and regulatory aspects of respiratory drug development.
Friday, October 28, 2011
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos